Aditxt (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced publication of a mathematical model for predicting the durability and rate of decay of neutralizing antibodies to SARS-CoV-2 in a peer-reviewed research paper in the Journal of Theoretical Biology. The publication, titled “A mathematical model of the within-host kinetics of SARS-CoV-2 neutralizing antibodies following COVID-19 vaccination,” describes a model developed with Dr. Lisette de Pillis, a professor of life sciences and mathematics at Harvey Mudd College. NAb inhibit viral binding to the human cell receptor thereby reducing ability to infect the cell. The researchers state that evaluating NAb levels and their durability over time is important in understanding unique immune responses and the likelihood of an individual having protective immunity against infection. The AditxtScore(TM) model utilizes a novel flow-cytometry-based immune monitoring tool to determine levels of NAb following immunization.
To view the full press release, visit https://ibn.fm/1jnzX
About Aditxt Inc.
Aditxt is a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system. Aditxt’s immune monitoring technologies are designed to provide a personalized immune profile. Aditxt’s immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases and allergies. For more information, please visit www.Aditxt.com and www.AditxtScore.com.
NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
